Although research on IDO1 inhibitors has progressed to phase III clinical trials, the controversy surrounding their mechanisms in cardiovascular disease has prevented clinical trials using IDO1 inhibitors for treating cardiovascular diseases. Here, IDO1 is linked to cardiovascular disorder.